Drug Trial Radar · NCT06831370
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a test to check how well a participant's lungs work. Each participant will undergo a final health status check 2 months after the last treatment with brentuximab vedotin plus AVD.
Conditions
- Hodgkin Lymphoma
Interventions
Brentuximab VedotinDrug
Brentuximab Vedotin IV infusion
DoxorubicinDrug
Doxorubicin IV infusion
VinblastineDrug
Vinblastine IV infusion
DacarbazineDrug
Dacarbazine IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), and Unexpected ADRsTime frame: Up to 40 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
AIIMS
New Delhi, India · Recruiting
HCG City Cancer Centre
Vijayawada, Andhra Pradesh, India · Recruiting
Gauhati Medical college and Hospital
Guwahati, Assam, India · Active not recruiting
Unique Hospital Multispeciality and Research Institute
Surat, Gujarat, India · Recruiting
HCG Cancer Centre
Bangalore, Karnataka, India · Recruiting
JIPMER
Puducherry, Kerala, India · Active not recruiting
HCG Manavata Cancer Centre
Nashik, Maharashtra, India · Active not recruiting
ACTREC
Navi Mumbai, Maharashtra, India · Active not recruiting
DMH
Pune, Maharashtra, India · Active not recruiting
Rajiv Gandhi Cancer Hospital
Delhi, New Delhi, India · Active not recruiting
NRS Medical college & Hospital, Kolkata
Kolkata, West Bengal, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.